SOURCE: Signal Watch

Signal Watch

April 11, 2012 08:15 ET

Analytical Reports on Hospira Inc. and Valeant Pharmaceuticals International - Drug Delivery Companies Expanding Reach and Offerings

NEW YORK, NY--(Marketwire - Apr 11, 2012) - www.SignalWatcher.com provides members with proprietary analysis of over 10,000 stocks which is updated every day. Today, members can receive their complimentary stock analysis on Hospira Inc. (NYSE: HSP) and Valeant Pharmaceuticals International (NYSE: VRX). Sign up now on www.SignalWatcher.com to get your free reports on these stocks.

The precipitous patent cliff currently facing the whole pharmaceutical industry is making companies with diversified revenue streams increasingly attractive. With potential for both long-term income opportunities and good stability, companies producing both generic and proprietary drugs are now regarded by many as something of a safe heaven.

www.SignalWatcher.com brings investors free classic analysis on Hospira Inc., Valeant Pharmaceuticals International and other companies within the Drug Delivery industry. This type of analysis is only a fragment of the information members have available to them. To learn more we encourage investors to sign up at http://signalwatcher.com/EmailSignup.php.

Many companies in the drug delivery industry, such as Valeant Pharmaceuticals International, seem to be looking to acquisitions and partnerships as a way to expand their offerings and geographies. Last fiscal year, Valeant made several acquisitions and seems intent on continuing its growth. The company recently announced its acquisition of a 19.9 percent stake in a Brazilian biotech company as well as its agreement to acquire Russian pharmaceutical company Natur Produkt International. www.SignalWatcher.com gives traders a unique insight about Valeant Pharmaceuticals International by registering now at http://signalwatcher.com/VRX/April112012.php.

Keeping pipelines flowing is also an important way of boosting income, though securing FDA clearance is always a major hurdle. Hospira Inc. recently announced that the FDA has cleared its Symbiq 3.13 infusion pump, which should be available to previously contracted customers during the second quarter of this year. www.SignalWatcher.com gives traders a unique insight about Hospira Inc. by registering now at http://signalwatcher.com/HSP/April112012.php.

About Signal Watch

Signal Watch's #1 goal is to help customers successfully engage the markets. For over 20 years, we have been developing the most powerful trading software available anywhere. But the software is only part of our mission. We also provide education and customer support designed to enable our customers to take control of their financial future.

Read our disclaimer by clicking on the following link http://www.signalwatcher.com/disclaimers.php

Contact Information